Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
10:38am, Monday, 30'th Jun 2025
The biotechnology company's messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna's influenza vaccine superior to licensed shot in study
07:22am, Monday, 30'th Jun 2025
Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu shot in adults aged 50 years and older in a late-stage study.
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
07:00am, Monday, 30'th Jun 2025
Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
07:00am, Monday, 30'th Jun 2025
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRI
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
06:51pm, Thursday, 26'th Jun 2025
In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.
Moderna (MRNA) Advances While Market Declines: Some Information for Investors
06:51pm, Friday, 20'th Jun 2025
In the most recent trading session, Moderna (MRNA) closed at $25.90, indicating a +1.97% shift from the previous trading day.
Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript
04:44pm, Monday, 16'th Jun 2025
Moderna, Inc. (NASDAQ:MRNA ) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ET Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Rose Loughlin - Exec
Here's Why Moderna (MRNA) Fell More Than Broader Market
06:51pm, Friday, 13'th Jun 2025
Moderna (MRNA) closed the most recent trading day at $26.68, moving 2.45% from the previous trading session.
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
08:42am, Friday, 13'th Jun 2025
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
07:35pm, Thursday, 12'th Jun 2025
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
07:25pm, Thursday, 12'th Jun 2025
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the
Is it Time to Dump Your Shares of Moderna?
04:25am, Thursday, 12'th Jun 2025
After soaring to success in the early days of the COVID-19 pandemic, Moderna (MRNA 0.25%) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this f
Moderna, Inc. (MRNA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
08:38pm, Wednesday, 11'th Jun 2025
Moderna, Inc. (NASDAQ:MRNA ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ET Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Salveen
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
07:00am, Wednesday, 11'th Jun 2025
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
11:50am, Tuesday, 10'th Jun 2025
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus
